---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022627"
form_type: "8-K"
ticker: "GNLX"
cik: "0001231457"
company_name: "GENELUX Corp"
filed_at: "2023-06-27T23:59:59+00:00"
generated_at: "2026-06-13T16:02:56.286409+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Genelux provides Phase 3 enrollment timeline for Olvi-Vec and cash runway into Q1 2026

## Summary
- Enrollment for Phase 3 trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer expected to complete mid-2024 with 11-month follow-up.
- Initial interim data for Phase 2 trial of Olvi-Vec in recurrent non-small-cell lung cancer expected as early as mid-2024.
- Cash operating runway expected to extend into first quarter of 2026.

## SEC filing metadata
- accession: 0001493152-23-022627
- form_type: 8-K
- ticker: GNLX
- cik: 0001231457
- company_name: GENELUX Corp
- filed_at: 2023-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1231457/000149315223022627/0001493152-23-022627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1231457/000149315223022627/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022627
- JSON: https://secwatch.observer/filing/0001493152-23-022627.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022627.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.